PIN7 Community Health Center Pharmacist's Impact on Latino Immunization Rates  by Jiang, S. et al.
abine/tenofovir and efavirenz are the most frequently prescribed drugs after diag-
nosis of HIV. More research, however, is required to better understand adverse
events and side effects.
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OBJECTIVES: Healthy People 2020 (HP2020) emphasized the use of community ser-
vices for prevention and treatment of infectious diseases. Pharmacists are in a
unique position to helpwith this goal. This study comparednational immunization
rates to immunization rates of Hispanic patients receiving clinical pharmacist in-
terventions in a community health center (CHC). METHODS: El Paso CHC Latino
patients who were referred to a clinical pharmacist for diabetes and met immuni-
zation criteria between January 1, 2010 to December 31, 2010 were included. The
pharmacist documented whether or not the patient met criteria for Hepatitis A
(HepA), Hepatitis B (HepB), Tetanus-diphtheria-acellular pertussis (Tdap), Pneumo-
cocal, Zoster and Influenza vaccines. If criteria were met and patient consented,
the vaccine(s) were administered. Vaccination rates were calculated by dividing
the number of patients vaccinated by the number of eligible patients. Study immu-
nization rates (SIRs) were comparedwith the latest available (2009) national overall
(OIRs) and the Hispanic immunization (HIRs) rates. RESULTS: For included patients
(N336), HepA SIR was 32.7%, which was higher than both the OIR (9.8%) and HIR
(8.5%). The Zoster SIR (10.1%)was similar to the OIR (10.0%), but higher than theHIR
(4.8%). The Pneumococal SIRs (46.2%: 19-64 years; 65 years: 39.4%) were higher
than HIR in both age groups (12.1%, 40.4%, respectively). It was only higher, how-
ever, in the overall group aged 19-64 years (17.5%), but not in the 65 age group
(60.6%). The influenza SIR was 27.1%, which was higher than the HIR (22.0%), but
lower than the OIR (33.6%). The SIR for HepB (14.6%) and Tdap (42.0%) were lower
than both national rates (HIR:41.8%, 36.7%; and OIR:50.8%, 48.7%, respectively).
CONCLUSIONS: Pharmacist’s immunization rates among Latino patients were
higher when compared to Hispanic national rates for HepA, Zoster, and Pneumo-
cocal and influenza. Community pharmacists can play an instrumental role in
reducing infectious diseases health disparities.
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OBJECTIVES: Ceftaroline fosamil (CPT, TEFLARO
®
) is a new, broad-spectrum, bac-
tericidal cephalosporin approved in the US for the treatment of community-ac-
quired bacterial pneumonia (CABP). In two randomized controlled CABP trials
(NCT00621504, NCT00509106), clinical cure rates in the modified intent-to-treat
(MITT) efficacy population were 82.6% for CPT and 76.6% for ceftriaxone. Response
rates at Day 4 (MITT population, N141) were 69.6% and 58.3% for CPT and ceftri-
axone. The objective was to assess the budgetary impact of adding CPT to a US
hospital formulary. METHODS: A three-year hospital budget impact model was
constructed to evaluate patients hospitalized with CABP requiring intravenous (IV)
antimicrobial therapy and having PORT risk class scores of III or IV. Patients were
randomized to receive CPT 600mg IV q12h or 1g ceftriaxone IV q24h for 5–7 days.
Clinical cure rates were assumed to be similar to those from CPT phase 3 CABP
trials. Patients failing initial treatment were assumed to be treated successfully
with second-line antibiotic therapy. Length of stay and total cost per hospital day
(by success or failure with initial treatment) were estimated based on a large data-
base from over 100 US hospitals. Other model inputs included: annual number of
CABP admissions; projected annual case growth rate; proportion of CABP target
population initially treated with ceftriaxone; expected proportion of CABP target
population to be treated with CPT; drug cost; cost of antibiotic administration; cost
of second-line antibiotic therapy for patients failing initial therapy. A sensitivity
analysis using 95% confidence limits of clinical cure rates from phase 3 trials pro-
vided varying estimates. RESULTS: Estimated total cost for treating a CABP patient
with CPT is $1102 lower ($18,925 vs. $20,027) than treating a similar patient with
ceftriaxone (sensitivity analysis range: -$6 to -$2,223). CONCLUSIONS: Model esti-
mates indicate adding ceftaroline to formulary does not negatively impact a hos-
pital CABP budget.
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OBJECTIVES: Daptomycin is a cyclic lipopeptide antibiotic that has been commer-
cially available in Europe since 2006. Daptomycin has rapid bactericidal activity
against MRSA and is indicated for gram-positive infections including complicated
skin and skin structure infections (cSSSI), right-sided infective endocarditis and
Staphylococcus aureus bacteremia (BSI). This study aims to quantify the budgetary
impact of utilizing Daptomycin for suspected gram-positive cSSSI and BSI in
Germany.METHODS: A budget impact model was developed to compare the total
direct costs of utilizing vancomycin, linezolid, daptomycin, and “other antibiotics”
as a single category. A decision tree was constructed on the basis of clinical guide-
lines and validated by clinicians. Clinical data and laboratory utilization and cost
data were derived from a comprehensive review of over 40 publications. Antibiotic
utilization and net drug costs were derived using syndicated data from Arlington
Medical Resources (AMR). RESULTS: On average, the total direct costs (drug acqui-
sition, lab monitoring, and hospital) of treating a cSSSI patient with the following
agents were: vancomycin €2598 (4%, 12% and 84%), linezolid €2742 (37%, 5%, and
58%), daptomycin €3,171 (30%, 7%, and 63%), and other antibiotics €1835 (2%, 10%,
and 88%). For BSI patients, total direct costs were: vancomycin €2359 (5%, 13% and
82%), linezolid €3951 (37%, 5%, and 58%), daptomycin €2135 (37%, 7%, and 56%), and
other antibiotics €3087 (4%, 10%, and 86%). Extrapolating these costs to an average
German hospital with 300 BSI and 1000 cSSSI patients and increasing daptomycin
use in BSI from 1% to 6% and in cSSSI from 0.3% to 1.4% would save the hospital
€30,151 and €2,971 per year, respectively. CONCLUSIONS: Using daptomycin for
treating cSSSI is budget neutral and using it for bacteremia patients is associated
with favorable economic outcomes when compared with other antibiotics.
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OBJECTIVES: Ceftaroline fosamil (CPT, Teflaro
®
) is a new, broad-spectrum, bacte-
ricidal cephalosporin approved in the United States for the treatment of acute
bacterial skin and skin structure infections (ABSSSI). In two randomized controlled
ABSSSI trials (NCT00424190, NCT00423657), clinical cure rates in the modified in-
tent-to-treat (MITT) population were 85.9%with CPT and 85.5%with vancomycin
aztreonam. Clinical response rates at Day 3 (MITT population, N797) were 74.0%
and 66.2% for CPT and vancomycin  aztreonam combination, respectively. The
objective was to assess the budgetary impact of adding CPT to a hospital formulary
in the United States. METHODS: A three-year hospital budget impact model was
constructed with three initial treatment options; CPT, vancomycin  aztreonam,
and other vancomycin-containing regimens. The target population was hospital-
ized adult, ABSSSI patients. Clinical cure rateswith initial treatmentwere assumed
to be similar to those fromCPT clinical trials. Patients failing initial treatment were
assumed to be treated successfully with a second-line antibiotic therapy. Length of
stay and cost per hospital day (by success or failure with initial treatment) were
estimated based on a large database from over 100 US hospitals. Other model
inputs included: annual number of ABSSSI admissions; projected annual case
growth rate; proportion of ABSSSI target population receiving vancomycin-con-
taining regimen; expected proportion of ABSSSI target population to be treated
with CPT; drug acquisition cost; cost of antibiotic administration; cost of vancomy-
cin monitoring. A sensitivity analysis using 95% confidence limits of clinical cure
rates provided varying estimates. RESULTS: Estimated total cost for treating an
ABSSSI patient with CPT is $313 lower ($13,804 vs. $14,117) than vancomycin 
aztreonam (sensitivity analysis range; $235 to -$833) and $71 lower ($13,804 vs.
$13,875) than other vancomycin-containing regimens (sensitivity analysis range;
$478 to -$1430). CONCLUSIONS: Model estimates indicate adding ceftaroline to
formulary does not negatively impact a hospital ABSSSI budget.
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OBJECTIVES: Assess economic costs of adverse events (AEs) among patients with
human immunodeficiency virus (HIV) treated with non-nucleoside reverse trans-
criptase inhibitors (NNRTIs) including delavirdine, efavirenz, etravirine, and
nevirapine. METHODS: Retrospective cohort study using medical and pharmacy
claims fromUS commercial orMedicare supplemental insurance patients between
January 1, 2004 to September 30, 2009. Adult HIV-patients initiating NNRTI (no
NNRTI use during 6 months prior to first dispensation [index date]) were selected.
AEs included rash, nausea/vomiting, diarrhea, dizziness, headache, sleep-related
symptoms, hepatotoxicity, lipid disorders, depression, anxiety, and self-injury. AE
episode-related care during the year post-initiation was identified by claims asso-
ciated with AE management. AE cases were matched 1:4 to non-AE controls by
propensity of having anAE. “Associated costs” included plan payments and patient
copayments directly related to managing AEs. “Incremental costs” of experiencing
an AE were calculated as the difference in total costs between patients with AE
during the period of each AE episode and non-AE controls (matched period).
RESULTS: The study included 2548 NNRTI users (mean age 43 years; 84%male; 87%
efavirenz; 29% experienced an AE). During 1-year post-index period, annual total
healthcare cost per patient in this study populationwas $27,751 (efavirenz: $26,704;
other NNRTIs: $34,993). Annual mean AE associated costs were $609 per patient
(efavirenz: $555; other NNRTIs: $979). Mean AE associated cost of care (duration)
per AE episode ranged from $586 (88 days) for lipid disorders, $975 (33 days) for
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